Skip to main content

Table 2 Summary of the reports on GH axis evaluation and treatment in patients with TRPS I

From: A novel TRPS1 gene mutation causing trichorhinophalangeal syndrome with growth hormone responsive short stature: a case report and review of the literature

 

Patients (gender)

Genetic diagnosis

GH status

Chronological age at GH start

Bone age at GH start

Pubertal staging

GH dose mg/kgnwk

Height SDS change

Naselli et al. 1998 [11]

Patient 1 (F)

Not reported

Deficient, based on GH stim test and IGF1 level, no data

11.1 y

8–9 y

Prepubertal

0.23

None

Patient 2 (F)

Not reported

Deficient, based on GH stim test and IGF1 level, no data

11.1 y

8–9 y

Prepubertal

0.23

None

Stagi et al. 2008 [13]

Patient 3 (M)

Not reported

Partial deficiency, Peak after arginine 6.8, after insulin 12.7, low nocturnal GH 2.7

12 y

9 y 6 m

G2, PH2, T4 ml bilaterally

0.26

+ 0.7 SDS over 5 years

Patient 4 (M)

c2722C > T (p.R908X)

Partial deficiency. Peak after Clonidine 10.2, peak after insulin5.4, low nocturnal GH 2.38

9 y 9 m

7 y8 m

Prepubertal

0.26

+ 1.9 SDS over 7 years

Sarafoglou et al. 2010 [14]

Patient 5 (M)

Not reported

No deficiency. Low IGF1 and normal IGFBP3

7 y

~3 y delay

Prepubertal

0.3–0.43

+1.81 SDS over 3 years

Patient 6 (F)

Not reported

No deficiency. Low IGF1 and normal IGFBP3

6.95 y

~ 6 m delay

Prepubertal

0.34–0.54

+1.95 SDS over 2 years

Sohn et al. 2012 [12]

Patient 7 (F)

c2520dupT (p.Arg841LysfsX3)

Deficient (peak after insulin 3.17 and after L-dopa 5)

4 y

2.6 y

Prepubertal

0.2

+ 0.4 SD over 10 years

Patient 8 (M)

c1630C > T (p.Arg544X)

Not deficient (peak after glucagon 9.86, after L-dopa 9.7)

14 y

16 y

Pubertal

Not reported

None (1 cm over 6 months)